Sunday, March 30th, 18:15 Opening ceremony – General (Cavaniglia 1)

On-site (live stream) General Cavaniglia 1	
Sunday, March 30, 18:15 – 19:45	
GS1 Opening Ceremony	
Chair: Anna Sureda (Barcelona, Spain) Chair: Fabio Ciceri (Milano, Italy)	
GS1-1 Welcome and introduction Speaker: Anna Sureda (Barcelona, Spain)	
GS1-2 Welcome and introduction to the conference Speaker: Fabio Ciceri (Milano, Italy)	
GS1-3 EBMT Patient Advocacy Committee: Welcome note Speaker: Natacha Bolaños (Madrid, Spain)	
GS1-4 Welcome from the Nurses Group Speaker: Michelle Kenyon (London, United Kingdom of Great Britain and Northern Ireland (the))	
GS1-5 Honorary Members 2025 Speaker: Catherine Cordonnier (Créteil, France) Speaker: Myriam Labopin (Paris, France) Speaker: Norbert Schmitz (Hamburg, Germany) Speaker: Gerard Socie (France)	
GS1-6 Introduction to the Tribute lecture Speaker: Fabio Ciceri (Milano, Italy) Speaker: Paolo Muraro (London, United Kingdom of Great Britain and Northern Ireland (the))	
GS1-7 Tribute lecture - HSCT in MS: from experimental procedure to standard of care Speaker: Gianluigi Mancardi (Genova, Italy)	

GS1-8 Introduction of the Keynote speakers Speaker: Fabio Ciceri (Milano, Italy)

GS1-9 Keynote lecture - Gene therapy: from bench to bedside journey Speaker: Luigi Naldini (Milan, Italy) Speaker: Franco Locatelli (Rome, Italy)

Monday, March 31st

11:00-12:30 Nurses group Diseases update - Dante (Spadolini 1)

R Greco 11:00-11:21, what is new in AD

On-site (live stream) Nurses Group Dante (Spadolini -1)

Monday, March 31, 11:00 - 12:30

NG08 Disease update

Accredited by the Italian Commission of Medical Education (CME)

Chair: Iwona Przewozna (Poznan, Poland) Chair: Claudia Boglione (Florence, Italy)

NG08-1 What is new in autoimmune disease?

Speaker: Raffaella Greco (Milano, Italy)

NG08-2 Immunodeficiencies

Speaker: Ignacio González (Madrid, Spain)

NG08-3 Aplastic anaemia

Speaker: Kelly Hennessy (London, United Kingdom of Great Britain and Northern Ireland (the))

NG08-4 Myelodysplastic neoplasms (MDS)

Speaker: Dominiek Mazure (Gent, Belgium)

NG08-5 Q&A

14:30-15:45 Oral session Hemopoiesis and biology of cell therapy complications -Raffaello (Spadolini 1)

M Doglio14:57-15:06, sHLH incidence and characteristics

On-site (live stream) Oral Session Raffaello (Spadolini -1)

Monday, March 31, 14:30 - 15:45

OS04 Oral Session 4 | Hemopoiesis and biology of cell therapy complications

Chair: Parastoo B. Dahi (New York, United States of America (the)) Chair: Mathias Schäfersküpper (Hamburg, Germany)

OS4-01 RECONSTRUCTING SKELETAL HOMEOSTASIS THROUGH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS Oral Presenter: Mathias Schäfersküpper (Hamburg, Germany)

OS4-02 CLONAL HAEMATOPOIESIS IN PATIENTS WITH AUTOIMMUNE DISEASE UNDERGOING AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT Oral Presenter: David D. Ma (Sydney, Australia)

OS4-03 PROPHYLACTIC ANAKINRA FOR TOXICITY MITIGATION IN HIGH-RISK CD19-CAR-T PATIENTS: A REAL-WORLD DATA SET FROM THE ROYAL MARSDEN HOSPITAL

Oral Presenter: Jack Taylor-Stuart (London, United Kingdom of Great Britain and Northern Ireland (the))

OS4-04 "REAL WORLD" INCIDENCE AND CHARACTERISTICS OF IMMUNE EFFECTOR CELL-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTICYTOSIS: A GOCART COALITION STUDY ON BEHALF OF THE EBMT ADWP, CTIWP AND TCWP

Oral Presenter: Matteo Doglio (Milan, Italy)

OS4-05 LATE HEMATOTOXICITY OF CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL IN PATIENTS WITH LARGE B CELL LYMPHOMA (LBCL): THE ANALYSIS OF CELL THERAPY CONSORTIUM

Oral Presenter: Parastoo B. Dahi (New York, United States of America (the))

OS4-07 MICROBIAL METABOLITES: DUAL ROLES IN MODULATING CAR-T CELL THERAPY

Oral Presenter: Markus Perl (Regensburg, Germany)

OS4-08 T-ICAHT: A NOVEL GRADING SYSTEM TO CHARACTERIZE THROMBOCYTOPENIA AND ITS PROGNOSTIC RELEVANCE IN CAR-T THERAPY Oral Presenter: Jaime Sanz (Valencia, Spain)

Monday, March 31st

16:30-18:00 Presidential symposium – General (Cavaniglia 1) *K. Kirgizov, 17:51-18:00, Complications after aHSCT for AD*

On-site (live stream) General Cavaniglia 1

Monday, March 31, 16:30 - 18:00

GS2 Presidential Symposium

Accredited by the Italian Commission of Medical Education (CME)

Chair: Anna Sureda (Barcelona, Spain) Chair: Fabio Ciceri (Milano, Italy)

GS2-1 Van Bekkum Award - Introduction

GS2-2 INITIAL RESULTS OF THE LUMINICE-203 STUDY INVESTIGATING ACIMTAMIG WITH OFF-THE-SHELF ALLOGENEIC NATURAL KILLER CELLS (ALLONK[®]) IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA Oral Presenter: Gunjan L. Shah (New York, United States of America (the))

GS2-3 Basic Science Award - Introduction

GS2-4 PREVALENCE AND ORIGIN OF CLONAL HEMATOPOIESIS IN LONG-TERM SURVIVORS OF PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION Oral Presenter: Konradin Müskens (Utrecht, Netherlands (the))

GS2-5 NSAIDS: A SIMPLE THERAPY FOR MANAGING GHOSAL HEMATODIAPHYSEAL DYSPLASIA, A RARE BONE MARROW FAILURE DIAGNOSIS WORTH CONSIDERING

Oral Presenter: Jonathan Bordat (Paris, France)

GS2-6 COMPARISONS OF GLUCAGON-LIKE PEPTIDE-2 ANALOG APRAGLUTIDE IN COMBINATION WITH RUXOLITINIB FOR STEROID-REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE WITH MAGIC CONTROL COHORT: THE PHASE 2 STARGAZE TRIAL Oral Presenter: Robert Zeiser (Freiburg, Germany)

GS2-7 IMPACT OF DONOR TYPES IN ALLOGENEIC TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR SEVERE APLASTIC ANEMIA: A COMPARATIVE STUDY OF THE SAAWP EBMT

Oral Presenter: Juan Montoro (Valencia, Spain)

GS2-8 TDI-01 IN THE TREATMENT OF MODERATE TO SEVERE CHRONIC GRAFT-VERSUS-HOST DISEASE: INTERIM RESULTS FROM A MULTICENTER, OPEN-LABEL PHASE IB/II STUDY

Oral Presenter: Xiaodong Mo (Beijing, China)

GS2-9 TRANSPLANTATION OUTCOMES AFTER TBI/ETOPOSIDE IN ADOLESCENTS AND YOUNG ADULTS COMPARED TO CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA: DOES AGE MATTER?

Oral Presenter: Charlotte Calvo (Paris, France)

GS2-10 LATE COMPLICATIONS AFTER AUTOLOGOUS HSCT FOR AUTOIMMUNE DISEASES: A RETROSPECTIVE SURVEY FROM THE AUTOIMMUNE DISEASES WP (ADWP) AND TRANSPLANT COMPLICATIONS WP (TCWP) OF THE EBMT Oral Presenter: Kirill Kirgizov (Moscow, Russian Federation (the))

9:00-10:15, ADWP session- Firenze (Spadolini 1)

On-site (live stream) Working Party Session Firenze (Spadolini 1)

Tuesday, April 1, 09:00 - 10:15

ADWP Autoimmune Diseases Working Party Session

Chair: Tobias Alexander (Berlin, Germany) Chair: Elisa Roldan Galvan (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))

ADWP-1 Welcome

ADWP-2 Patient selection and best conditioning regimen for HSCT in MS Speaker: Alice Mariottini (Florence, Italy)

ADWP-3 Current position of HSCT in the treatment landscape of systemic sclerosis Speaker: Nicoletta Del Papa (Milano, Italy)

ADWP-4 Emerging indications for CAR T cell therapy in autoimmune diseases Speaker: Fabian Müller (Erlangen, Germany)

ADWP-5 Autologous HCT in rheumatic indications: consensus and best practice recommendations from the EBMT practice harmonization and guidelines committee.

Speaker: Elisa Roldan Galvan (Sheffield, United Kingdom of Great Britain and Northern Ireland (the))

ADWP-6 Q&A

9:00-10:30 Workshop Pulmonary coomplications Giotto (Spadolini 1) *D Farge,10:00-10:30, Lung fibrosis in SSc*

On-site (live stream) Workshop Giotto (Spadolini -1)

Tuesday, April 1, 09:00 - 10:30

W04 Pulmonary complications

Accredited by the Italian Commission of Medical Education (CME)

Chair: Adriana Balduzzi (Monza, Italy) Chair: Eolia Brissot (Paris, France)

W04-1 Is it infection? Optimal diagnostic strategies in evaluation of lung lesions Speaker: Anne Bergeron (Geneva, Switzerland)

W04-2 Challenges in diagnosis of lung GvHD: a multidisciplinary approach Speaker: Saskia Bos (Leuven, Belgium)

W04-3 Lung fibrosis in SSc after HCT and MSC Speaker: Dominique Farge (PARIS, France)

11:00-12:15, Oral session Aplastic anaemia & AD- Firenze (Spadolini 1)

On-site (live stream) Oral Session Firenze (Spadolini 1)

Tuesday, April 1, 11:00 – 12:15

OS12 Oral Session 12 | Aplastic Anaemia & Autoimmune Diseases

Chair: Flore Sicre de Fontbrune (Paris, France) Chair: Giorgio Orofino (Milan, Italy)

OS12-01 EFFECTIVENESS OF NON-MYELOABLATIVE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS PATIENTS (MS) AND FACTORS ASSOCIATED WITH BETTER OUTCOMES Oral Presenter: Denis Fedorenko (Moscow, Russian Federation (the))

OS12-02 CO-INFUSION OF CD19/BCMA-TARGETED CAR-T CELLS ERADICATES AUTOANTIBODY-PRODUCING CELLS IN SLE PATIENTS:A PHASE 1 CLINICAL TRIAL

Oral Presenter: Jingjing Feng (Hangzhou, China)

OS12-03 OUTCOMES OF PATIENTS WITH ACQUIRED APLASTIC ANEMIA RECEIVING MATCHED RELATED DONOR TRANSPLANT: A MULTICENTER STUDY ON BEHALF OF PAKISTAN BLOOD AND MARROW TRANSPLANT GROUP Oral Presenter: Natasha Ali (Karachi, Pakistan)

OS12-04 COMPARISON OF DIFFERENT ANTI-HUMAN T CELL GLOBULINS ON IMMUNE RECONSTITUTION AND EARLY INFECTIONS AFTER CYCLOPHOSPHAMIDE-BASED CONDITIONING FOLLOWED BY AUTOLOGOUS TRANSPLANT IN PATIENTS WITH MULTIPLE SCLEROSIS Oral Presenter: Johanna Richter (Hamburg, Germany)

OS12-05 HLA HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH SEVERE APLASTIC ANEMIA: A GATMO-TC EXPERIENCE Oral Presenter: Ana Lisa Basquiera (Córdoba, Argentina)

OS12-06 EARLY MORBIMORTALITY IN AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION PERFORMED ON OUTPATIENT BASIS IN PATIENTS WITH AUTOIMMUNE DISEASES: EXPERIENCE IN 1700 PATIENTS

Oral Presenter: Guillermo J. Ruiz-Argüelles (Puebla, Mexico)

OS12-07 ADENOSINE DEAMINASE 2 DEFICIENCY: A NOVEL GENETIC CAUSE OF BONE MARROW FAILURE SYNDROMES Oral Presenter: Federica Barzaghi (Milan, Italy)

OS12-08 FRESH AUTOLOGOUS CD19-TARGETING CAR T CELLS (CD19-CART) FOR PEDIATRIC PATIENTS WITH SEVERE/REFRACTORY AUTOIMMUNE DISEASE (AD)

Oral Presenter: Marco Becilli (Rome, Italy)

14:30-16:00, Joint physician-nurse session Transplant & Cell therapy in AD-Raffaello (Spadolini 1)

On-site (live stream) Special Session Raffaello (Spadolini -1)

Tuesday, April 1, 14:30 – 16:00

SS7 Joint physician-nurse session | Achieving best outcomes in transplant and cell therapy for autoimmune disease. Opportunities and optimisation Chair: Raffaella Greco (Milano, Italy)

Chair: Claudia Boglione (Florence, Italy)

Panel discussion session on achieving the best outcomes in transplant and cell therapy for autoimmune disease:

SS7-1 HSCT in neurological ADs

SS7-2 Transplant outcome

SS7-3 Infections focus and long-term complication

SS7-4 The future of HSCT and other treatments

Patient perspective

Panelist: Noelle Tassy (Marseilles, France) Panelist: Susanne Baerlin (Berlin, Germany)

Physiotherapist perspective

Panelist: Cristina Bozzolini (Firenze, Italy)

Nurse perspective

Panelist: Claudia Boglione (Florence, Italy) Panelist: Davide Bonomi (Milan, Italy)

Disease specialist perspective Panelist: Basil Sharrack (United Kingdom of Great Britain and Northern Ireland (the))

HSCT specialist perspective Panelist: Richard Burt (United States of America (the))

SS7-5 Closing remarks

16:30-18:00, Workshop New IEC approaches - Ronda

J Richter , 17:00-17:30, CAR in AD

On-site (live stream) Workshop Ronda

Tuesday, April 1, 16:30 - 18:00

W07 New IEC approaches

Accredited by the Italian Commission of Medical Education (CME)

Chair: Dominique Farge (PARIS, France) Chair: Alina Daniela Tanase (Bucharest, Romania)

W07-1 New and dual CAR Targeting

Speaker: Marcela Maus (Boston, United States of America (the))

W07-2 CAR in autoimmune diseases Speaker: Johanna Richter (Hamburg, Germany)

W07-3 CAR-T in solid tumors

Speaker: Monica Casucci (Milano, Italy)

18:00-19:00, Posters AD – Firenze (Spadolini 1)

Breaks **Printed Poster** Firenze (Spadolini 1)

Tuesday, April 1, 18:00 - 19:00

Autoimmune Diseases

B299 BONE MARROW HEMOPOIESIS IN PRE-TREATED MULTIPLE SCLEROSIS BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION

B300 HIGH DOSE IMMUNOSUPPRESSIVE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS: QUALITY OF LIFE ANALYSIS

B301 EARLY THERAPEUTIC RESPONSE AS A PROGNOSTIC INDICATOR IN AUTOLOGOUS HSCT FOR MULTIPLE SCLEROSIS

B302 IMPACT OF BMI ON HEMATOPOIETIC STEM CELL TRANSPLANT OUTCOMES IN MULTIPLE SCLEROSIS PATIENTS

B303 ASSOCIATION OF SMOKING WITH DISEASE PROGRESSION IN PERSONS WITH MULTIPLE SCLEROSIS UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE-**CENTER EXPERIENCE**